AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00380770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d > 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
Study NCT00393796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUTENT
Description: 50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248.
Study NCT00393796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUTENT
Description: 50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248.
Study NCT00393796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00955851 — intervention group
Intervention type: OTHER
Intervention: Pre and post vaccination titers
Description: Titers will be obtained pre vaccination and 4 weeks post vaccination
Study NCT03932734 — intervention group
Intervention type: OTHER
Intervention: survey
Description: Face-Q conversion table
Study NCT04344691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus femoris stretching
Description: Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
Study NCT05436769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaribact 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study NCT05436769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klaribact 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study NCT05436769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study NCT05436769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klaricid 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study NCT02626481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
Study NCT02626481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
Study NCT02342366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB 35 mg/kg p.o.
Description: GHB 35 mg/kg p.o.
Study NCT02342366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GHB 35 mg/kg p.o.
Description: GHB 35 mg/kg p.o.
Study NCT02342366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB 20 mg/kg p.o.
Description: GHB 20 mg/kg p.o.
Study NCT02342366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GHB 20 mg/kg p.o.
Description: GHB 20 mg/kg p.o.
Study NCT01524133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Study NCT01524133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: up to 13 sessions of prolonged exposure
Study NCT04323839 — intervention group
Intervention type: OTHER
Intervention: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19
Description: This is an observational study with no intervention
Study NCT04323839 — intervention group
Intervention type: OTHER
Intervention: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19
Description: This is an observational study with no intervention
Study NCT00232583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg/BID
Study NCT00232583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin Novolg 70/30 per protocol titration
Study NCT00232583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metfomin
Description: Metformin 1000mg/BID
Study NCT00225732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline as placebo comparator
Description: 250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
Study NCT00225732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ibuprofen
Description: 800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
Study NCT02684825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring
Description: Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
Study NCT02051413 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine extended release
Description: antidepressant drug
Study NCT00232583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45mg
Study NCT00232583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: Glyburide per protocol titration
Study NCT03743883 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic Acid(BAYE4465, Aspirin )
Description: Administration according to clinical practice
Study NCT01878643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin or gentamicin
Description: Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
Study NCT01878643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline administered to patient via nebulization
Study NCT02890758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) Cells
Description: Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT
Study NCT02890758 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Natural Killer (NK) Cells
Description: Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT
Study NCT02890758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT803
Description: given at 6mcg/kg weekly for four weeks
Study NCT02722382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Centered Kidney Transitions Care
Description: In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
Study NCT02479945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Obtaining biospecimen
Study NCT01981239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFSS
Description: VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
Study NCT01981239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VFSS
Description: VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
Study NCT03869281 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreas transplantation alone
Description: Pancreas transplantation
Study NCT04611438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Intervention schedule for each patient is as follows:~1. Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~2. Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~   * Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~  * Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~  * Maintenance: no change in medication dosage
Study NCT03842163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of TTR amyloidosis cardiomyopathy
Description: Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
Study NCT00041080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT00041080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00041080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01698866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccin GenHevac B Pasteur
Study NCT03877978 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nephrocheck test
Description: Nephrocheck® measurement on urine sample at different timepoints.
Study NCT02811055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement
Description: Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Pressure Measurement
Description: Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrocardiogram
Description: Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electrocardiogram
Description: Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthostatic test
Description: Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: orthostatic test
Description: Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Aprepitant
Description: Administration of Aprepitant 80 mg once per day during 14 days
Study NCT02811055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Administration of placebo once per day during 14 days
Study NCT04992325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior segment-optical coherence tomography
Description: Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
Study NCT01009827 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
Study NCT00233688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QUANTUM LP™ STENT GRAFT SYSTEM
Description: Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
Study NCT00233688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical repair
Description: Open surgical repair
Study NCT01924013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
Study NCT01924013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
Study NCT01924013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
Study NCT01867671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy - Liquid Extract
Description: Used during initial dose escalation for doses 0.1 to 0.8 mg.
Study NCT01867671 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Peanut Oral Immunotherapy - Liquid Extract form
Description: Similar in appearance, texture, and taste to peanut liquid extract.
Study NCT01867671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy - Peanut Flour
Description: This will be used for the remainder of dose escalation, build-up, and maintenance.
Study NCT01867671 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Peanut Oral Immunotherapy - Peanut Flour
Description: Similar in appearance, texture, and taste to peanut flour.
Study NCT03449290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
Study NCT03449290 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio taping
Description: Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
Study NCT00589394 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: pneumococcal vaccination (Pneumovax)
Description: pneumovax was given
Study NCT02910531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: Already mentioned in arm/group descriptions.
Study NCT02910531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Already mentioned in arm/group descriptions.
Study NCT04399785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camrelizumab and SBRT
Description: Camrelizumab: 200mg every 3 weeks; SBRT
Study NCT03525106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Receive positive psychology manual
Study NCT03525106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete positive psychology exercises
Study NCT03525106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03525106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03525106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Participate in phone sessions
Study NCT00741325 — intervention group
Intervention type: DRUG
Intervention: granulocyte colony-stimulating factor (G-CSF)
Study NCT00741325 — intervention group
Intervention type: DRUG
Intervention: plerixafor
Study NCT00741325 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT04345081 — intervention group
Intervention type: PROCEDURE
Intervention: Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction
Description: Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
Study NCT04345081 — intervention group
Intervention type: PROCEDURE
Intervention: Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery
Description: Classic Skin- Sparing Mastectomy
Study NCT03210272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT03210272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Tablet
Study NCT03210272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (Test)
Description: Fasting state
Study NCT03210272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (Reference)
Description: Fed state
Study NCT01292447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Description: 120mg lidocaine x 1
Study NCT01292447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Inert gel x 1
Study NCT01156233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: Cuff palpation technique: identification of the cuff position in the trachea by palpation.
Study NCT01156233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
Study NCT03039023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline Bitartrate
Description: 500mg choline bitartrate tablets
Study NCT03039023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-cooked, pre-peeled whole hardboiled eggs
Description: Obtained from a commercial source.
Study NCT03039023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg whites from pre-cooked, pre-peeled hardboiled eggs
Description: Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.